Jpmorgan Chase & CO Protagonist Therapeutics, Inc Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 576,977 shares of PTGX stock, worth $22.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
576,977
Previous 502,985 14.71%
Holding current value
$22.3 Million
Previous $22.6 Million 1.47%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
BUY
$38.51 - $48.43 $2.85 Million - $3.58 Million
73,992 Added 14.71%
576,977 $22.3 Million
Q3 2024

Dec 26, 2024
BUY
$33.72 - $47.33 $4.26 Million - $5.98 Million
126,397 Added 33.56%
502,985 $22.6 Million
Q3 2024

Nov 08, 2024
BUY
$33.72 - $47.33 $4.26 Million - $5.98 Million
126,397 Added 33.56%
502,985 $22.6 Million
Q2 2024

Dec 26, 2024
SELL
$24.66 - $34.8 $3.12 Million - $4.4 Million
-126,397 Reduced 25.13%
376,588 $13 Million
Q2 2024

Aug 12, 2024
BUY
$24.66 - $34.8 $3.43 Million - $4.84 Million
139,148 Added 58.6%
376,588 $13 Million
Q1 2024

Dec 26, 2024
SELL
$21.79 - $32.15 $5.79 Million - $8.54 Million
-265,545 Reduced 52.79%
237,440 $6.87 Million
Q1 2024

May 10, 2024
SELL
$21.79 - $32.15 $3.78 Million - $5.58 Million
-173,606 Reduced 42.24%
237,440 $6.87 Million
Q4 2023

Dec 26, 2024
SELL
$14.05 - $23.44 $1.29 Million - $2.16 Million
-91,939 Reduced 18.28%
411,046 $9.43 Million
Q4 2023

Feb 12, 2024
BUY
$14.05 - $23.44 $2.51 Million - $4.19 Million
178,756 Added 76.95%
411,046 $9.43 Million
Q3 2023

Nov 14, 2023
SELL
$16.68 - $23.66 $540,715 - $766,986
-32,417 Reduced 12.25%
232,290 $3.87 Million
Q2 2023

Aug 11, 2023
BUY
$18.02 - $29.36 $2.86 Million - $4.66 Million
158,574 Added 149.41%
264,707 $7.31 Million
Q1 2023

May 18, 2023
BUY
$10.78 - $25.38 $384,231 - $904,619
35,643 Added 50.56%
106,133 $2.44 Million
Q1 2023

May 11, 2023
SELL
$10.78 - $25.38 $2.51 Million - $5.91 Million
-232,672 Reduced 76.75%
70,490 $1.62 Million
Q4 2022

Feb 13, 2023
BUY
$7.36 - $11.17 $939,158 - $1.43 Million
127,603 Added 72.68%
303,162 $3.31 Million
Q3 2022

Nov 14, 2022
BUY
$7.86 - $11.71 $432,803 - $644,799
55,064 Added 45.7%
175,559 $1.48 Million
Q2 2022

Aug 11, 2022
BUY
$7.06 - $25.52 $362,262 - $1.31 Million
51,312 Added 74.17%
120,495 $954,000
Q1 2022

May 11, 2022
SELL
$23.34 - $36.08 $8.57 Million - $13.3 Million
-367,270 Reduced 84.15%
69,183 $1.64 Million
Q4 2021

Feb 10, 2022
BUY
$17.63 - $37.1 $136,773 - $287,821
7,758 Added 1.81%
436,453 $14.9 Million
Q3 2021

Nov 12, 2021
BUY
$12.95 - $49.69 $5.55 Million - $21.3 Million
428,695 New
428,695 $7.6 Million

Others Institutions Holding PTGX

# of Institutions
254
Shares Held
58.9M
Call Options Held
189K
Put Options Held
191K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.9B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email